Select Page ::

Pattern Raises Additional $9M to Fast-track New Technology for the Fight Against Antibiotic Resistance – PRNewswire

Posted on July 14, 2020 by Danzig

AUSTIN, Texas, July 14, 2020 /PRNewswire/ --Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development and clinical validation of its Digital CultureTM rapid bacterial identification and susceptibility testing (ID/AST) technology.

Illumina Venturesled the Series B-1 funding and was joined by the lead investor from Pattern's previous two rounds, Omnimed Capital. As part of the transaction, Nick Naclerio, Founding Partner of Illumina Ventures, will join Pattern's Board of Directors. The funding will supplement the company's previously announced CARB-X awardas the company works toward FDA clearance of its patented clinical microbiology diagnostics platform.

"Antibiotic resistance is one of the biggest threats to global health today and its effects are compounded by the current global pandemic. We desperately need a fundamental shift in the way common bacterial infections are treated," said Nick Naclerio, Founding Partner of Illumina Ventures. "Pattern is poised to unlock a new paradigm in targeted antibiotic treatment through faster and smarter diagnostics."

Digital CultureTM is a single cell analysis platform that uses digital cell reactors combined with machine learning to rapidly diagnose complex bacterial infections. The platform, which produces millions of measurements per run, will zoom into the real-time antibiotic response of individual bacterial cells within the first critical hours of illness.

Pattern's phenotypic testing platform is uniquely suited to address all common bacterial infections, including complex infections such as pneumonia, that elude other rapid antibiotic susceptibility testing technologies. This is particularly important during COVID-19, when more patients are hospitalized and in need of mechanical ventilation. Ventilated patients are at high risk of developing bacterial pneumonia and are often treated with antibiotics days before current antibiotic susceptibility tests can be completed. Pattern's faster bacterial tests can reduce the risk of antibiotic misuse and enable focused treatment, improving patient outcomes and reducing selective pressures that lead to drug resistance.

"These funds will allow us to bring our life-saving technology a step closer to market," said Pattern Co-founder and CEO Nick Arab. "With COVID-19 pulling us deeper into the antibiotic resistance crisis, there is an even greater need for rapid tests that can takethe guesswork out of critical treatment decisions for complex infections. Illumina Ventures and Omnimed share this vision and we're excited to have their support for Pattern's next phase."

About Pattern

Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance.Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps.Pattern's Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in more comprehensive and reliable diagnoses compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.

About Illumina Ventures

Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness. For more information, visitwww.illuminaventures.com

About Omnimed Capital

Omnimed Capital specializes in venture capital and private equity healthcare investments. Omnimed's investment strategy is grounded in the view that healthcare is transitioning toward personalized care and prevention tailored to specific circumstances, diseases and patient individualities. The principals of Omnimed, a Concorde Company, have invested in numerous successful healthcare services and medical technologies.

SOURCE Illumina Ventures

Home

Follow this link:

Pattern Raises Additional $9M to Fast-track New Technology for the Fight Against Antibiotic Resistance - PRNewswire

Transitioning to technology in turbulent times | 2020-07-14 | Dairy Foods – dairyfoods.com

Posted on July 14, 2020 by Danzig

Transitioning to technology in turbulent times | 2020-07-14 | Dairy Foods This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more. This Website Uses CookiesBy closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.

See the original post here:

Transitioning to technology in turbulent times | 2020-07-14 | Dairy Foods - dairyfoods.com

Insights Into the Consumer Water Purifier Industry, 2020-2025 by Technology, End-use, Mobility, Distribution Channel and Region -…

Posted on July 14, 2020 by Danzig

DUBLIN--(BUSINESS WIRE)--The "Consumer Water Purifier Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

The global consumer water purifier market was valued at US$17.344 billion in 2019.

The market for consumer water purifiers is projected to witness healthy growth over the course of the next five years majorly on account of the rising concerns regarding the benefits of clean drinking water especially in the underdeveloped economies where the purchasing power is comparatively low. The rapid growth in the number of deaths due to water-related diseases is one of the leading causes for the inclination of the people towards water purification systems. According to the statistics from the World Health Organization, around 3.4 million people die each year due to water-related diseases, and the WHO states these can be mitigated to some extent with the use of various inexpensive purification systems.

Furthermore, the rapid urbanization in the developing economies of the region coupled with a rise in the middle-class population in various countries including India, China, Brazil, and Indonesia among others are also some of the key factors propelling the demand for water purification systems, thereby driving the market growth during the next five years. Furthermore, the improvement in standards of living is also driving the demand for water purifiers in the undeveloped and developing economies as well. Also, the availability of clean water and safe water by municipalities of various countries has also led to a decent increase in the adoption of water purifiers, this, in turn, is also projected to positively impact the consumer water purifier market growth.

Rapid technological advancements is driving the market growth significantly

The rapidly growing consumer requirements have led to the constant participation by the key market players for the development and launch of new products with an aim to expand their market share and gain a competitive edge over other players. For instance, recently in February 2020, Havells India Limited, one of the leading FMEG Company based out of India, announced the launch of its latest Delite Alkaline High Recovery, eco-friendly water purifier with 50%+ water recovery. In addition, during the same month, Livpure announced the launch of a new product line up for its water purifier segment.

Similarly, in August 2019, Kent RO Systems announced the launch of a new purifier product KENT Ace Star RO Water Purifier. Furthermore, the investments by new market players in the market for entering into new business segments are also considered to be a prime factor supporting the market growth during the next five years. For example, in September 2019, Xiaomi Corporation announced the launch of its latest product offering Mi Smart Water Purifier for its sale in India.

Also, booming investments in the form of R&D and rising inclination of key market players for the development of new products in concern with various social issues. For instance, in December 2019, Kent announced its latest technology that is aimed towards zero wastage of water; the company also states that not even a single drop of water will be wasted.

Furthermore, in October 2016, Blue Star, a globally known manufacturer of air conditioners, commercial refrigeration systems announced its entry into a new business segment of residential water purifiers. All these factors are collectively contributing to the consumer water purifier market growth throughout the forecast period.

The market is also poised to grow on account of the rising government focus towards the development of commercial infrastructure that includes, hotels, airports, metros, shopping malls, movie theatres, and commercial buildings such as offices. The booming initiatives by the governments of various countries is also propelling the opportunities for the key manufacturers and vendors to invest more in the market and gain a competitive edge over other players.

For instance, Saudi Arabia and UAE have their main focus in the development of commercial infrastructure which is indicated from the fact, there are various initiatives taken by the government of major countries like Saudi Vision 2030, UAE Vision 2021 and UAE Vision 2023 that include the construction of new hotels, airports, and metros. This, in turn, is also expected to add up to the requirements of commercial water purifiers, thus driving the market growth during the next five years.

Asia Pacific to hold a considerable market share

The Asia Pacific region is projected to hold a considerable market share throughout the forecast period. The major factor bolstering the share of the APAC region includes the presence of a considerably large population base across the region especially in countries like India and China among others. Furthermore, the growing middle-class population and rapid urbanization in the developing countries of the region is also a key factor bolstering the growth during the next five years. Also, the presence of key players of the market in the region is further supplementing the market growth throughout the forecast period.

Competitive Insights

Prominent key market players in the consumer water purifier market include Eureka Forbes, KENT RO, TATA, and A.O Smith among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the consumer water purifier market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.

Market Segmentation

By Technology

By End-use

By Mobility

By Distribution Channel

By Geography

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/v4pu0i

Map: surveillance technology used by police departments across the US – Business Insider – Business Insider

Posted on July 14, 2020 by Danzig

Despite Americans' reverence for freedom and liberty, it's virtually impossible for even law-abiding citizens to avoid being constantly watched by their government. And law enforcement agencies, aided by newer and more advanced technologies, are keeping a closer eye on them than ever before.

There are 50 million security cameras in the US one for every six people, more per capita than in China according to Precise Security. A government watchdog found the FBI's facial recognition database contains more than 641 million images. Axon Enterprise, the nation's largest supplier of body cameras, recently told investors that the company is eyeing an $11 billion market.

And in a recent privacy assessment, the US Customs and Border Protection acknowledged that it's "unrealistic" for Americans to avoid being tracked by its network of license plate readers.

That's especially true when the opaque and often invisible nature of surveillance technology makes it difficult for Americans to understand when and how extensively they're being monitored.

But a new, first-of-its-kind project aims to help demystify the government's reach. The Atlas of Surveillance, a crowdsourced database compiled by the Electronic Frontier Foundation and hundreds of students from the University of Nevada Reno, uses publicly available information to map state and local law enforcement agencies' use of surveillance technologies across the US.

Previously, researchers and journalists have typically focused on identifying either which technologies are used by a specific agency like the New York Police Department, or which agencies are using a specific technology, such as facial recognition software.

However, EFF's database is unique in that it maps the use of 12 different tools including facial recognition, license plate readers, body cameras, fake cellphone towers, gunshot detectors, and drones across nearly 4,000 police departments. By doing so, it paints a more comprehensive picture of at least 5,300 cases of surveillance tech being deployed nationwide.

"It's a little overwhelming to look at but that's because the surveillance state is overwhelming," Dave Maass, a senior researcher at EFF and visiting professor at UNR who led the project, told Business Insider.

Maass said it's particularly concerning "how all of these individual technologies are converging together." At digital command hubs called real-time crime centers, everything from social media posts to camera footage is analyzed live by "a sophisticated algorithm" and shared with multiple agencies in order to help them identify potential crimes and allocate resources, he said.

While the database is far from complete and will be continually updated, Maass said EFF decided to release it now given the renewed spotlight on surveillance technology amid recent protests against police brutality.

"People are protesting, they're noticing the body-worn cameras, they're noticing the strange trucks driving around with weird equipment in the back, they're noticing drones flying above," Maass said. "People are starting to realize as they're out on the street and they're having more interactions with police that technology matters."

Civil rights and privacy advocates, including EFF, have been sounding alarms about surveillance technology for years. They've cited concerns like body cameras' potential chilling effects on free speech at protests and a growing body of research showing that tools like facial recognition software and predicting policing algorithmsdiscriminate based on race and genderand exacerbate existing inequalities in the criminal justice system let alone scant evidence that these tools actually help keep communities safe.

As public opinion has shifted around policing, pressure has also mounted on the companies that supply surveillance tech to address flaws in their products or cut ties with law enforcement entirely. Last month, Amazon, Microsoft, and IBM bowed demands from employees and activists and agreed to pause sales of their facial recognition tools to law enforcement.

Hamilton based SteriRight launches N95 Mobile Mask Sanitizing Technology in Response to COVID-19 – Canada NewsWire

Posted on July 14, 2020 by Danzig

HAMILTON, ON, July 14, 2020 /CNW/ -N95 masks are recognized to provide the best protection against airborne biological particles but have been in very short supply. To help alleviate this problem, SteriRight is launching its state-of-the-art mobile technology that will allow organizations to quickly and affordably disinfect N95 face masks for re-use by their employees. SteriRight's mobile reprocessing unit, which kills 99.99% of common bacteria and viruses, including a surrogate for COVID-19 is now available to travel to businesses throughout the region to decontaminate N95 masks.

The launch of SteriRight's mobile service comes after the federal and provincial governments called on manufacturers to step up with solutions related to the COVID-19 pandemic. The launch took place today at McMaster Innovation Park where supporters had the opportunity to see the process in action. SteriRight's Health Canada Interim Order authorized technology sanitizes and decontaminates the users N95 masks for safe re-use. As Ontario re-opens its economy, PPE, in particular N95 respirators are in high demand. Latest data from the Government of Canada suggest only 10% of N95 masks ordered have been delivered.

The SteriRight process is unique in that it utilizes a hybrid, three-pronged decontamination approach using ultraviolet light (UV-C), ozone and vapourized hydrogen peroxide and takes under a minute. The mobility of the SteriRight unit means it can be quickly deployed to a location and allow organizations to keep employees safe, healthy and working. Masks can be disinfected up to 10 times and the original user will get their own mask back after it is decontaminated.

"We are thrilled to be able to step up and provide Ontario businesses with this important technology and service. Our technology which is the only mobile technology authorized by Health Canada allows businesses to safely serve their customers while their employees have access to sanitized masks," said Bay Area Health Trust CEO Peter Kalra, "we are hoping to support businesses return to a safe environment for their customers and employees".

Launched with the support of Synapse Life Science Consortium, Alex Muggah, Director of Synapse stated, "We are proud to support SteriRight as they demonstrate this mobile sanitization technology. At Synapse, we focus on facilitating the commercialization of health innovations. Hamilton has many COVID related projects underway and we are confident that Hamilton businesses will benefit from SteriRight's N95 mask decontamination services".

To learn more about SteriRight mobile sanitation services please visit: https://steriright.ca/

About SteriRight

SteriRightwas born as a result of the COVID-19 pandemic, and particularly the crisis of personal protective equipment (PPE) availability. Critical shortages of PPE triggered Health Canada to look for innovative solutions from reprocessors of disposable N95 respirators and from manufacturers of reprocessing equipment to meet current needs, and the gradual return to the "new normal" meant that organizations had to think about their office or work environment cleaning differently.

SteriRight is a Hamilton based start-up backed by its parent company Bay Area Health Trust and is managed by a dedicated team with significant experience in the health care and life science industries.

Currently focused on the sanitization and reprocessing, SteriRight's future will include an expansion of equipment and services such as building and facility disinfecting. Learn more at http://www.steriright.ca

About Bay Area Health Trust

At the intersection of health, life sciences and business, Bay Area Health Trust is an example of a successful partnership between hospitals and the private sector. Leveraging its unique affiliation with Hamilton Health Sciences, McMaster University and the other members of the Synapse Life Science Consortium, Bay Area Health Trust promotes entrepreneurship and invests in growth-oriented businesses to support patient care. Learn more at http://www.bayareahealthtrust.com

SOURCE SteriRight

For further information: Contact, Peter Kalra, President and CEO, 905-521-2248 ext.73766, [emailprotected]

See original here:

Hamilton based SteriRight launches N95 Mobile Mask Sanitizing Technology in Response to COVID-19 - Canada NewsWire

Understanding 5G, the fifth generation of smart network; how the technology works and how it will change our lives? – Jagran English

Posted on July 14, 2020 by Danzig

5G is available on three different types of spectrums - Low-band, Mid-band and High-band Spectrum.

New Delhi | Jagran Tech Desk: The succession of smart telecommunication networks, from first generation analogue voice, 1G (in 1980s) to the fourth generation LTE, 4G (from 2010s onward) had started to leap towards 5G in 2019, whose pace although got hindered due to COVID-19 pandemic in 2020, but has gained momentum yet again. 5G, the fifth generation telecommunication standard that began to replace the already available fourth generation LTE in a few pockets and boroughs of various parts of the world, is expected to eventually replace or at least supplement the already-available 4G, just like 4G started replacing 3G, and 3G its predecessors before that.

How 5G works?

Unlike its predecessors, the 5G is available on three different types of spectrums, each of which requires a specific antenna for its transmission, also implying to the availability of better network spaces due to multiplicity of options. There is Low-band Spectrum, Mid-band Spectrum, and High-band Spectrum, in decreasing order of the coverage. This simply means that although a low-band spectrum will have a wider coverage area, it will transmit lower network speed. Whereas a high-band spectrum will have smaller coverage area, but it will transmit the fastest network speeds. Each spectrum will differ in collateral and operational costs as well, depending on the demand or feasibility from the ends of respective service providers.

How fast is 5G?

This totally depends on the band that the service provider is providing to its users. According to a CNET report, even the low-spectrum 5G band will provide the downloading speed upwards of 400 MBPS, with a Los Angeles-installed AT&T high spectrum 5G network leading to peak download speed as high as 1.8 GBPS. In the pockets and boroughs of the UK, the US, South Korea, and Australia, where various service providers have already rolled out the 5G network, the average 5G downloading speed was recorded at close to 500 MBPS.

The report says that with 5G at its zenith, a two-hour movie could be downloaded in just 8.2 seconds with seamless pace.

What will change with the dawn of 5G?

The tech nerds and enthusiasts are anticipating the 5G network to eventually replace the currently available broadband services. Since a lightning-fast 5G network is meant not just for the smartphones, but also for other smart devices, such as smart TVs and real time lag free gaming devices among others, it is expected to usher an era of telecommunication far different from the one we already know about.

However, 5Gs rolling-out requires big-time investments depending on the low, mid, or high spectrum range a service provider decides to offer to its users. This means that with big-time speeds will come the higher costs for the users, and exclusive utilisation of the service, at least for initial some months after its rolling out, depending on how the market receives the successor of 4G.

Posted By: Abhinav Gupta

Read this article:

Understanding 5G, the fifth generation of smart network; how the technology works and how it will change our lives? - Jagran English

SpaceX’s next batch of Starlink satellites back on the launch pad – Spaceflight Now

Posted on July 14, 2020 by Danzig

EDITORS NOTE:Launch has been delayed to Saturday, July 11, at 10:54 a.m. EDT (1454 GMT).

SpaceX raised a Falcon 9 rocket vertical Tuesday on pad 39A at NASAs Kennedy Space Center, positioning the launch vehicle for a flight Wednesday carrying 57 more Starlink Internet satellites and two commercial Earth-imaging microsatellites for BlackSky.

The 229-foot-tall (70-meter) launcher was supposed to take off last month, but SpaceX called off a launch attempt June 26. The company said theteam needed additional time for pre-launch checkouts.

In the end, SpaceX delayed the launch 12 days, and the company opted to shuffle order of its launches.

A Falcon 9 rocket successfully launched June 30 from pad 40 at Cape Canaveral Air Force Station a few miles to the south of pad 39A with a U.S. military GPS navigation satellite. The Falcon 9 rocket loaded with the Starlink and BlackSky satellites rolled back to its hangar near pad 39A to await the missions next launch opportunity.

With the Falcon 9 standing atop pad 39A again Tuesday, SpaceXs launch team planned perform final checkouts on the rocket and commence the countdown early Wednesday.

The Falcon 9 will be filled with super-chilled, densified kerosene and liquid oxygen propellants beginning around 35 minutes prior to liftoff, which is timed for precisely 11:59:11 a.m. EDT (1559:11 GMT) Wednesday.

Theres a 60 percent chance of acceptable weather for a midday launch Wednesday, according to the U.S. Space Forces 45th Weather Squadron. Central Florida is in a typical summertime pattern of strong afternoon and evening thunderstorms, but forecasters said Tuesday that the latest computer model runs suggested storms may develop a bit earlier in the day Wednesday.

While the launch windows timeframe is still more favorable than later in the afternoon, some showers and storms moving in from the northwest cannot be ruled out, forecasters wrote. Because of this, the primary concern for the launch window is the cumulus cloud rule and the surface electric field rule.

If the weather conditions cooperate, nine Merlin engines will build up to produce 1.7 million pounds of thrust, driving the Falcon 9 launcher toward the northeast from Floridas Space Coast on the way to an orbit inclined 53 degrees to the equator.

The first stage booster launching Wednesday will make its fifth trip to space. It first flew from the Kennedy Space Center in March 2019 on an unpiloted test flight of SpaceXs Crew Dragon spacecraft, then launched again from Vandenberg Air Force Base in California in June 2019 with three Canadian radar observation satellites.

The reusable booster also launched two Starlink missions from Florida earlier this year, according to SpaceX.

The first stages nine engines will fire for around two-and-a-half minutes during launch, then the booster will fall away from the Falcon 9s upper stage. The booster will deploy four titanium grid fins for aerodynamic stability, and then fire three of its engines for a burn to target landing on SpaceXs drone ship Of Course I Still Love You holding position in the Atlantic Ocean around 400 miles (630 kilometers) northeast of Cape Canaveral.

A final burn of the first stages center engine, followed by lowering of the boosters four landing legs, will set up the rocket for touchdown on the floating landing vessel nearly eight-and-a-half minutes after liftoff. If the rocket sticks the landing, SpaceX will bring the booster back to Port Canaveral for inspections and refurbishment ahead of another flight.

While the first stage descends back to Earth from the edge of space, the Falcon 9s single-use upper stage will ignite its vacuum-rated Merlin engine to propel the missions 59 satellite payloads into orbit.

The rockets payload fairing, which protects the satellites during the initial phases of launch, will jettison from the Falcon 9 at T+plus 3 minutes, 24 seconds. SpaceXs two fairing recovery boats, named Ms. Tree and Ms. Chief, are on station in the Atlantic Ocean to retrieve the two fairing halves after they fall to Earth under parachutes.

The upper stage will shut down its engine at T+plus 8 minutes, 51 seconds, after reaching a preliminary parking orbit. A second firing of the Merlin upper stage engine more than 47 minutes after liftoff will place the 59 satellites into a near-circular orbitranging as high as an altitude of 249 miles (401 kilometers).

The two BlackSky satellites fastened on top of the 57 Starlink satellites will be the first payloads to deploy from the Falcon 9 rocket at T+plus 61 minutes and T+plus 66 minutes.

The Falcon 9 will next release retention rods holding the Starlink satellites to the rocket, allowing the flat-panel broadband relay stations to fly away from the launch vehicle around 1 hour, 33 minutes, after liftoff,

SpaceXs Starlink network is designed to provide low-latency, high-speed Internet service around the world. SpaceX has launched 538 flat-panel Starlink spacecraft since beginning full-scale deployment of the orbital network in May 2019, making the company the owner of the worlds largest fleet of satellites.

With Wednesdays launch, SpaceX will have delivered 595 Starlink satellites to orbit in the last 14 months.

Each of the flat-panel satellites weighs about a quarter-ton, and are built by SpaceX in Redmond, Washington. Once in orbit, they will deploy solar panels to begin producing electricity, then activate their krypton ion thrusters to raise their altitude to around 341 miles, or 550 kilometers.

SpaceX says it needs 24 launches to provide Starlink Internet coverage over nearly all of the populated world, and 12 launches could enable coverage of higher latitude regions, such as Canada and the northern United States.

The Falcon 9 can loft up to 60 Starlink satellites each weighing about a quarter-ton on a single Falcon 9 launch. But launches with secondary payloads, such as BlackSkys new Earth-imaging satellites, can carry fewer Starlinks to allow the rideshare passengers room to fit on the rocket.

The initial phase of the Starlink network will number 1,584 satellites, according to SpaceXs regulatory filings with the Federal Communications Commission. But SpaceX plans launch thousands more satellites, depending on market demand, and the company has regulatory approval from the FCC to operate up to 12,000 Starlink relay nodes in low Earth orbit.

Elon Musk, SpaceXs founder and CEO, says the Starlink network could earn revenue to fund the companys ambition for interplanetary space travel, and eventually establish a human settlement on Mars.

But astronomers have raised concerns about the brightness of SpaceXs Starlink satellites, and other companies that plan to launch large numbers of broadband satellites into low Earth orbit.

The Starlink satellites are brighter than expected, and are visible in trains soon after each launch, before spreading out and dimming as they travel higher above Earth.

SpaceX introduced a darker coating on a Starlink satellite launched in January in a bid to reduce the amount of sunlight the spacecraft reflects down to Earth. That offered some improvement, but not enough for ultra-sensitive observatories like the U.S government-funded Vera Rubin Observatory in Chile, which will collect all-sky images to study distant galaxies, stars, and search for potentially dangerous asteroids close to Earth.

SpaceX launched a satellite June 3 with a new unfolding radio-transparent sunshade to block sunlight from reaching bright surfaces on the spacecraft, such as its antennas.

All Starlink satellites beginning with the launch scheduled for Wednesday will carry the sunshade modification to reduce each spacecrafts optical reflectivity.

BlackSky, based in Seattle, is deploying a fleet of Earth observation satellites designed to monitor changes across Earths surface, feeding near real-time geospatial intelligence data to governments and corporate clients. The companys next two satellites set for launch Wednesday are the first off a new assembly line designed to produce spacecraft at a rate of one to two per month.

The BlackSky satellites set for launch Wednesday are designated Global 7 and Global 8, but they are actually the fifth and sixth operational satellites in the BlackSky fleet.

Scott Herman, BlackSkys chief technology officer, said the company iscomfortable working with SpaceX. Spaceflight Industries, BlackSkys parent company, has arranged rideshare missions on Falcon 9 rockets for other customers, and BlackSkys Global 2 satellite launched on a Falcon 9 flight in 2018.

Weve been working with SpaceX for a long time, Herman said. We do work with others the Indian space agency and Rocket Lab but weve had a pretty deep relationship with SpaceX, and were one of their largest customers outside the U.S. government because of all the different rides weve been brokering.

The BlackSky satellites launching Friday are the first produced by LeoStella, a joint venture between Spaceflight Industries and Thales Alenia Space, a major European satellite manufacturer. LeoStellas production facility is located in Tukwila, Washington, a suburb of Seattle.

Read more about the BlackSky satellites in our earlier story.

The BlackSky spacecraft each weigh around 121 pounds, or 55 kilograms. They have electrothermal propulsion systems that use water as a propellant.

Each of the current generation of BlackSky Global spacecraft can captureup to 1,000 color images per day, with a resolution of about 3 feet (1 meter).

Email the author.

Follow Stephen Clark on Twitter: @StephenClark1.

Here is the original post:

SpaceX's next batch of Starlink satellites back on the launch pad - Spaceflight Now

Global Stem Cell Therapy Market Growth, Share, Demand and Applications Forecast to 2024 – 3rd Watch News

Posted on July 14, 2020 by Danzig

The Global Stem Cell Therapy Market report is deep study of the present market dynamics. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecasted period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A significant development has been recorded by the market of Stem Cell Therapy, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A systematized methodology is used to make a Report on the Global Stem Cell Therapy market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports.

Request a sample of this report @ https://www.orbispharmareports.com/sample-request/14043?utm_source=Nilam

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global Stem Cell Therapy market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the Stem Cell Therapy market. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. For the analysis of market on the terms of research strategies, these techniques are helpful.

Browse the complete report @ https://www.orbispharmareports.com/global-stem-cell-therapy-market-2019-present-status-and-future-opportunities-by-major-companies-typs-and-applications-2024/?utm_source=Nilam

Potential consumers, market values, and the future scope for the Stem Cell Therapy market are explained thoroughly to the users in this report. The key players of Stem Cell Therapy industry, their product portfolio, market share, industry profiles is studied in this report. It is very important for the vendors to provide customers with new and improved product/ services in order to gain their loyalty.

Segmentation by Type:

AutologousAllogeneic

Segmentation by Application:

Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

The study of various segments of the global Stem Cell Therapy market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/14043?utm_source=Nilam

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

View original post here:

Global Stem Cell Therapy Market Growth, Share, Demand and Applications Forecast to 2024 - 3rd Watch News

A ‘safety switch’ for cell therapy based on nutrient deprivation – FierceBiotech

Posted on July 14, 2020 by Danzig

The early success of CAR-T cell therapies in treating some forms of blood cancer has sent oncology researchers on a quest to develop the technology to address a range of tumor types. But the risk that the modified immune cells could cause the potentially deadly side effect known as cytokine release syndrome has prompted an equally enthusiastic effort in the research community to find innovative ways to combat that problem.

London-based startup Auxolytic is developing safety switches for cell therapy that hingeon depriving them of nutrientsthey need to survive. The company was founded by University of Cambridge biochemist James Patterson, Ph.D., who is working with researchers at Stanford University to develop the switch.

In a new study, the researchers demonstrated their technique with a gene called UMPS that normally makes the nutrient uridine, which T cells need to grow and proliferate. When they knocked out the gene in human T cells and pluripotent stem cells, the cells became inactive within a week, they reported in the journal Nature Biotechnology.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

How would this work in people? The UMPS gene would be knocked out in the cell therapy during the engineering process, and then the patient receiving the treatment would take uridine supplements to replace the missing nutrient. If signs of side effects to the cell therapy emerge, the patient would stop taking the supplement.

RELATED: Improving CAR-T therapy for cancer by regulating 2 proteins

Auxolytic tested its technology in mice by treating them with UMPS-edited T cells and then monitoring them for the rejection response graft versus host disease (GvHD). The cells became inactive in the mice that were not fed uridine supplements.

Its the latest idea to emerge for improving the safety of cell therapies. Earlier this year, a team at the University of North Carolina at Chapel Hill published a study showing they could dampen cytokine release syndrome by modulating levels of an enzyme called SHP1. Last year, German scientists showed that Bristol Myers Squibbs leukemia drug Sprycel could temporarily pause the activity of CAR-T cells in mice, preventing cytokine release.

Auxolytic gets its name from a scientific principle called auxotrophy, which refers to the ability of cells to synthesize nutrients and other compounds they need to survive, Patterson explained in a statement. Pattersons goal is to work with CAR-T developers to incorporate the technology into their products, he said.

See more here:

A 'safety switch' for cell therapy based on nutrient deprivation - FierceBiotech

COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 – Daily Research…

Posted on July 14, 2020 by Danzig

"Global Thoracic Catheters Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Thoracic Catheters market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Thoracic Catheters Market. The report begins with the introduction on Thoracic Catheters Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Thoracic Catheters manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The Thoracic Catheters production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Thoracic Catheters Industry are:MedtronicTeleflexSmiths MedicalAtriumMedelaRedaxAtmosSorinArgonCook MedicalPAHSCODiversatek

Top Product Types Evaluated are:CatheterAnalogDigital

Top Applications studied are:PneumothoraxPleural EffusionOthers

To derive the vital Thoracic Catheters Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Thoracic Catheters Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Thoracic Catheters Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Thoracic Catheters Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Thoracic Catheters Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Thoracic Catheters Market. North America is expected to reach a higher market share followed by the European region. Demand for Thoracic Catheters products and its relevant applications across different market segments is growing rapidly.

Thoracic Catheters Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Thoracic Catheters Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Thoracic Catheters industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Thoracic Catheters Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 - Daily Research...

Animal Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -…

Posted on July 14, 2020 by Danzig

New Jersey, United States,- Latest update on Animal Stem Cell Therapy Market Analysis report published with extensive market research, Animal Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Animal Stem Cell Therapy industry. With the classified Animal Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Animal Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Animal Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Animal Stem Cell Therapy Market growth opportunities in the industry.

Animal Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Animal Stem Cell Therapy market size, volume and value, as well as price data.

Animal Stem Cell Therapy Market competition by top Manufacturers:

Animal Stem Cell Therapy Market Classification by Types:

Animal Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Animal Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Animal Stem Cell Therapy market:

Unveiling the geographical penetration of the Animal Stem Cell Therapy market:

The report of the Animal Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Animal Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Animal Stem Cell Therapy Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:

Animal Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -...

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the…

Posted on July 14, 2020 by Danzig

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company. Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.

The companies will leverage the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform which includes point of care (POCare) Networks, POCare Therapeutics and a POCare Technologiessuite of proprietary and in-licensed technologies that have been engineered to create customized processing systems. The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network, which includes leading hospitals and research institutes around the world. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.

Vered Caplan, CEO of Orgenesis, stated, This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world. We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform. We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.

Dr Miomir Kneevi, CEO of Educell, commented, We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies. This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educells ability to ensure safety in the process and help to reduce overall manufacturing costs.

Together, the companies are working to address significant unmet market needs for producing novel cell therapies in a cost effective, high quality and scalable manner. The joint clinical development program seeks to provide safe, simplified, and cost-effective processing in an automated and controlled environment from start to finish with minimal operator intervention.

About EducellEducell Ltd, established 1997, is a company focusing on the development of cell therapy products and is a registered cell and tissue establishment. The company is preparing cell therapy products for the treatment of articular cartilage, vesicouretral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use within the University Medical Centre Ljubljana and other clinical institutions in Slovenia under the hospital exemption rule supervised by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. The companys R&D department is dedicated to the development of innovative cell therapy products and also to the development of medical devices that enable stem cell isolation and application in the operation theatre.

Educells ImmunoArt cell therapy product was developed in 2014 and is based on ex vivo expanded allogeneic mesenchymal stromal/stem cells (MSC) isolated from bone marrow. Its immunomodulatory capacity has already been proven in the clinic for the treatment of graft versus host disease (GvHD) and Chrons disease. Additional information is available at: https://www.educell.si/en/

About OrgenesisOrgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the Point of Care to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all. Additional information is available at: http://www.orgenesis.com.

Notice Regarding Forward-Looking StatementsThis press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to effectively use the net proceeds from the sale of Masthercell, our ability to achieve and maintain overall profitability, the development of our POCare strategy, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31 2019, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis:Crescendo Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com

Read the original here:

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis' Proprietary POCare Technologies for the...

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And…

Posted on July 14, 2020 by Danzig

New Jersey, United States,- Latest update on Musculoskeletal Disorder Stem Cell Therapy Market Analysis report published with extensive market research, Musculoskeletal Disorder Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Musculoskeletal Disorder Stem Cell Therapy industry. With the classified Musculoskeletal Disorder Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Musculoskeletal Disorder Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Musculoskeletal Disorder Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Musculoskeletal Disorder Stem Cell Therapy Market growth opportunities in the industry.

Musculoskeletal Disorder Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Musculoskeletal Disorder Stem Cell Therapy market size, volume and value, as well as price data.

Musculoskeletal Disorder Stem Cell Therapy Market competition by top Manufacturers:

Musculoskeletal Disorder Stem Cell Therapy Market Classification by Types:

Musculoskeletal Disorder Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Musculoskeletal Disorder Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Musculoskeletal Disorder Stem Cell Therapy market:

Unveiling the geographical penetration of the Musculoskeletal Disorder Stem Cell Therapy market:

The report of the Musculoskeletal Disorder Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Musculoskeletal Disorder Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Musculoskeletal Disorder Stem Cell Therapy Market report

About Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

The rest is here:

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19 -…

Posted on July 14, 2020 by Danzig

HOUSTON--(BUSINESS WIRE)--Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company and a leader in Mesenchymal Stem Cell (MSC) banking and technology, recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Companys COVID-19 Phase II clinical trial evaluating Celltex-produced autologous (ones own) adipose tissue(fat)-derived Mesenchymal Stem Cells (AdMSCs) to provide immune support and prevent COVID-19. Medistar Corporation, a medical real estate company specializing in healthcare projects, and researchers in Texas have developed an air conditioning system that can catch and kill coronavirus 2 (SARS-CoV-2) in an effort to help both essential workers, schools and the general public combat the COVID-19 pandemic.

Former United States Secretary of Energy and Texas Governor, Rick Perry, recently listed both companies promising technologies during a national cable news broadcast when he discussed potential treatments to protect the public from the coronavirus. As a vaccine can take years to develop, Rick Perry has been paying close attention to treatments and therapies that are both effective and available and wants to ensure that the public is aware that there is hope on the horizon with new medical technology.

With the continued spread of COVID-19, Americans are looking for immediate hope and want to hear a message from leaders that there are opportunities and therapies that are not too far out into the future and that can fight this virus, said Mr. Perry. Celltex Therapeutics clinical trials to demonstrate Celltexs MSCs ability to be a powerful preventative against COVID-19, as well as a development from another company, Medistar Corporation, which worked with researchers to create a biodefense filter that goes into HVAC systems and kills 99.8% of the virus. These are incredible breakthroughs that could help curb the spread of COVID-19 in peoples bodies and their environments. Concerning Medistars biodefense filter in particular, it could represent an opportunity to enable our kids to return to school in September.

Celltexs Phase II multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and prophylactic efficacy of MSCs to prevent COVID-19 was approved to proceed by the FDA based on Celltexs long history of producing its own proprietary MSCs in its cGMP FDA-compliant lab for more than 9,000 therapies administered without any adverse reaction. Celltex is currently enrolling 200 subjects in the study who are classified as at higher risk for contracting COVID-19 (https://www.clinicaltrials.gov/ct2/show/NCT04428801) and who have not been infected. One hundred subjects will receive intravenous infusions of autologous MSCs produced by Celltex while 100 will receive placebo treatments. The primary efficacy endpoint of the study is to evaluate overall safety of Celltexs MSCs. The secondary objective is to demonstrate the efficacy of Celltexs MSCs as a prophylactic therapy for those at a high risk of contracting coronavirus to mitigate respiratory, pulmonary and pneumonia co-morbidities.

Celltex has dedicated years to researching safety and efficacy of using its own proprietary MSCs for those suffering from injuries, pain and maladies associated with autoimmune, vascular and other debilitating diseases, including inflammatory lung conditions, pneumonia and chronic obstructive pulmonary disease (COPD). Global studies utilizing MSCs have shown promising results for combatting symptoms and complications associated with COVID-19, and as a leading commercial MSC banking and technology company, Celltex has the unique ability to transition these initial findings into a clinical trial. I am optimistic that our findings will result in favorable outcomes that will improve lives today and for generations to come, said David G. Eller, Celltex Chairman and Chief Executive Officer.

Medistar Corporation and a team of researchers from University of Houston and Texas A&M University worked together to design and fabricate an efficient air disinfection system based on heated nickel (Ni) foam to catch and kill SARS-CoV-2. Virus test results at the Galveston National Laboratory revealed 99.8% of the aerosolized SARS-CoV-2 was caught and killed by a single pass through a Ni-foam-based filter when heated up to 200 C. Additionally, the same filter was also used to catch and kill 99.9% of Bacillus anthracis, an airborne spore. This study paves the way for preventing transmission of SARS-CoV-2 and other highly infectious airborne agents in closed environments, such as schools, daycares, hotels, restaurants, airplanes, office buildings, churches, cruise ships and more. The peer-reviewed study can be found published in Material Physics Today.

Monzer Houranis technology is the only technology proven to catch and kill actual SARS-CoV-2 on contact, instantaneously. When deployed, this technology will have a dramatic impact in helping decrease indoor transmission of COVID-19 and other biological pathogens, said Dr. Garrett Peel, MD, Executive VP of Medistar Corporation & Founding Partner of Integrated Viral Protection.

ABOUT CELLTEX THERAPEUTICS

Founded in 2011, Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company and a pioneer in Mesenchymal Stem Cell (MSC) technology. The company is the nations leading commercial MSC banking company and focuses on spearheading breakthroughs in regenerative medicine using MSCs. Celltex uses its own proprietary technology to isolate, cryopreserve and culture hundreds of millions of superior grade MSCs in its state-of-the-art, current Good Manufacturing (cGMP) and FDA-compliant laboratory. Celltex-produced MSCs are used in regenerative therapies for injuries and chronic pain, as well as many other conditions, including vascular, degenerative and autoimmune diseases. Celltexs intellectual property (IP) portfolio encompasses over 1,500 clients, who have received over 9,000 MSC therapies for various diseases without incurring any adverse events. To learn more about Celltex, visit http://www.celltexbank.com.

ABOUT MEDISTAR CORPORATION

Medistar Corporation is a real estate development company headquartered in Houston, Texas. As it has for over 45 years, Medistar specializes in the development, financing and acquisition of real estate across the United States. Complementing its longstanding focus of medical real estate development, Medistar actively develops multifamily, hospitality, entertainment, commercial, and mixed-use projects. In Houston, Medistar is developing the iconic 50-story Innovation Tower to complement its recently completed 35-story, 374-unit LATITUDE Med Center apartment tower and 22-story, 353-key InterContinental Houston Medical Center hotel at the Texas Medical Center. Please visit http://www.medistarcorp.com/ for more information.

Continued here:

Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19 -...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell…

Posted on July 14, 2020 by Danzig

Autologous Stem Cell and Non-Stem Cell Based Therapies Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/284124

Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Lion Biotechnologies, Caladrius Biosciences, Opexa Therapeutics, Orgenesis, Regenexx, Genzyme of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Autologous Stem Cell and Non-Stem Cell Based Therapies market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Autologous Stem Cell and Non-Stem Cell Based Therapies market for your business? It brings to light the consumption in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Autologous Stem Cell and Non-Stem Cell Based Therapies market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Autologous Stem Cell and Non-Stem Cell Based Therapies industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Autologous Stem Cell and Non-Stem Cell Based Therapies Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read the original:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell...

Rheumatoid Arthritis Stem Cell Therapy Market Trends, Outlook and Opportunity Analysis 2018 to 2028 – Cole of Duty

Posted on July 14, 2020 by Danzig

Global Rheumatoid Arthritis Stem Cell Therapy Market Growth Projection

The new report on the global Rheumatoid Arthritis Stem Cell Therapy market is an extensive study on the overall prospects of the Rheumatoid Arthritis Stem Cell Therapy market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Rheumatoid Arthritis Stem Cell Therapy market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the upcoming years.

The report suggests that the global Rheumatoid Arthritis Stem Cell Therapy market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Rheumatoid Arthritis Stem Cell Therapy market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market over the considered assessment period.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

The report clarifies the following doubts related to the Rheumatoid Arthritis Stem Cell Therapy market:

Segmentation of the Rheumatoid Arthritis Stem Cell Therapy Market

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Vital Information Enclosed in the Report

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

View original post here:

Rheumatoid Arthritis Stem Cell Therapy Market Trends, Outlook and Opportunity Analysis 2018 to 2028 - Cole of Duty

Researchers at U of T use stem cells to grow functional blood vessel cells found in liver – News@UofT

Posted on July 14, 2020 by Danzig

An inter-disciplinary team of researchers, funded by the University of Torontos Medicine by Design,hasgeneratedfunctional blood vessel cells found in the liver from stem cells a discovery thatoffersan opportunityto study the rolethe cellsplayin liver developmentand diseaseprogression, and which couldlead tonew therapies to treat hemophilia A.

Thestudy, titledGeneration of Functional Liver Sinusoidal Endothelial Cells from Human Pluripotent Stem Cell-Derived Venous Angioblasts,waspublished this week in Cell Stem Cell. Itrepresents a collaborative effort betweenbasic and clinical researchersat U of T and the University Health Network (UHN)with expertise in stem celland computationalbiology,human liver physiology and functionand liver transplantation.

It alsodraws onprevious Medicine by Design-funded research that led to the creationin 2018of the first single-cell map of the human liver.

By combining insights from developmental biology and liver anatomy with thecellatlasof the human liver,we were able to generateand validatefunctional human liver vasculature from stem cells, saysBlair Gage,apost-doctoral researcher at the McEwen Stem Cell Institute at UHNand lead author ofthestudy.Nowwe canmove forwardto use these liver endothelial cells tobetterunderstandtheir role in liver functionand to develop new therapies to treat disorderssuch ashemophilia A.

Theinterdisciplinary researchteam also includes:JeffLiu,research associate atU of TsDonnelly Centrefor Cellular andBiomolecularResearch;Brendan Innes, a PhD candidate at the Donnelly Centre and in thedepartment ofmolecular genetics in the Faculty of Medicine;Sonya MacParland, scientist in themulti-organ transplant program at theToronto General Hospital Research Institute andan assistant professor in U of Ts departments of immunology andlaboratory medicine and pathobiology; Ian McGilvray,senior scientist at themulti-organ transplant program at theToronto General Hospital Research Institute and a professorinU of Ts department of surgery;Gary Bader, professor at the Donnelly Centreandthedepartment ofmolecular genetics; andGordon Keller,director andsenior scientist at theMcEwen Stem Cell Institute at UHNandprofessor in U of Ts department of medical biophysics.

Researchersinthe Keller lab had the goal of generatinga functional liver vasculature cell type known as liver sinusoidal cells (LSECs)fromhuman pluripotent stem cells (hPSCs) cells that can self-renew and have the potential to turn into any other cell type in the human body. LSECs are essential for normal liver function and represent the main source of factor VIII,a blood-clotting protein that is missing or defective in patients with hemophilia A.

However, the teamhad todemonstratethatthecellstheyhadmadein the labhad thesamespecializedgenetic and functionalfeaturesasthose in thehuman liver.So they turned to the work of MacParland, Bader and McGilvray,whoin the first phase ofMedicine by Designs team projectfundingdescribed amolecularmap of the cell types in the adult liver.Thatresearchhascontributed totheHuman Cell Atlasan international effort to create comprehensive reference maps of all human cellsand last yearattracted follow-on funding from the Chan Zuckerberg Initiative.

This paper uses our human liver map as a guide to know if the cells beinggeneratedaretherightones through collaboration with Gary Baders group, says MacParland.The work really highlights thestrengthof MedicinebyDesignin bringingtogether researchers from multiple institutionstofocus on a common goal.

With Bader and Lius help, Keller lab researchers were able to use the MacParlandhuman livermapto show that thehPSC-derivedendothelialcellsthey had generatedshared manyof thefeatures found innormal liver vasculature. The Keller lab team then brought Innes on board toformat thedatafromthehPSC-derived LSECsfor the research communitytoeasilyexplorethe molecular profile of these cells.

This research was supported by Medicine by Design, which receives funding from the federal governmentsCanada First Research Excellence Fundand by theCanadian Institutes of Health Research.

The work continues in a current Medicine by Design-funded team projectled by Kellerthat aims to make other key liver cell types and put together the pieces to get functional tissueswith the goal of developing new cell-based therapies for liver-related diseases.That project is part ofanew $20-million round of team project fundingthat Medicine by Design announced late last year.

Medicine by Designbrings togetherinvestigatorsfromdifferent disciplinesatU of T and its affiliated hospitals to advance new discoveries in regenerative medicine and accelerate them toward clinical impact.Medicine by Designwill host ameeting of the Human Cell Atlass Development and Pediatric Atlasin July 2021in Toronto.

See the article here:

Researchers at U of T use stem cells to grow functional blood vessel cells found in liver - News@UofT

Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026…

Posted on July 14, 2020 by Danzig

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Advanced Therapy Medicinal Products market.

Trusted Business Insights presents an updated and Latest Study on Advanced Therapy Medicinal Products Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Advanced Therapy Medicinal Products market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Advanced Therapy Medicinal Products Market Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Advanced Therapy Medicinal Products Market

The global advanced therapy medicinal products market size was valued at USD 3.14 billion in 2019 and is projected to expand at a CAGR of 17.4% during the forecast period. Recent advancements in biological therapies have resulted in a gradual shift toward personalized medicine from the conventional one-size fits all approach. The advanced therapy medicinal product (ATMP) landscape is one of the active spaces in this new trend. These products offer solutions for conditions with negligible therapeutic alternatives as well, which is one of the major growth drivers for the market.Although the regulation for ATMPs is currently in its nascent stage, it is a constantly developing area. The number of Investigational New Drug (IND) applications for these therapies continues to increase. Post-approval of Yescarta, Center for Biologics Evaluation and Research has received around 150 INDs in fiscal year 2018. According to the Alliance for Regenerative Medicine (ARM), more than 1,000 clinical trials were carried out for the ATMP designation to the products, by January 2019, globally.

With the approval of Luxturna, Yescarta, and Kymriah, this market has witnessed several acquisitions intended for market entry or expansion in the sector. For example, acquisition of Kite Pharma by Gilead Life Science, Juno Therapeutics by Celgene, and AveXis by Novartis are some of the notable acquisitions that took place in recent times. These acquisitions indicate the rising interest of major pharma companies in advanced therapy medicinal products.Although the companies have successfully secured product approvals in the past years, the high cost of therapies and challenges with respect to financial sustainability are anticipated to slowdown product adoption. Several products have been pulled off from the market as they were not considered financially viable for the developers as well as the payers. Moreover, some companies like Fibrocell have also witnessed the wind-down of their product operations.Despite the above-articulated challenges, this field is constantly expanding owing to the health benefits offered by these new classes of therapies, along with benefitting society and the healthcare system in context to healthcare outcome and resource availability. Considering the efficiency and clinical benefits of advanced therapy medicinal products, various stakeholders of the market are constantly designing strategies to overcome the existing challenges and spur advanced therapy medicinal products usage.TherapyType Insights of Advanced Therapy Medicinal Products Market

Over the past few years, there has been a notable increase in the clinical development of advanced therapies, including gene therapies, cell therapies, and tissue engineering products. Several products have already secured approval in U.S., China, Europe, South Korea, Japan, Australia, Canada, India, and New Zealand. As a result, a substantial number of well-established as well as start-up pharma companies, universities, and hospitals are shifting their focus from conventional therapies to advanced therapies.Cell therapies held the largest revenue share of the advanced therapy medicinal products market in 2019. Increased funding from governments as well as private organizations to support cell therapy clinical trials, improving the legal framework for cell therapy manufacturing and implementation, and proven efficacy of products are some of the key drivers for the growth of the segment.

Based on cell types, stem cell therapies held the dominant revenue share in 2019 owing to the presence of a substantial number of approved therapies. The entry of new players such as Celularity, Rubius Therapeutics, Century Therapeutics, Fate Therapeutics, ViaCyte, Magenta Therapeutics, ReNeuron, Promethera Biosciences, Frequency Therapeutics, and Cellular Dynamics in the recent years reflects the expanding stem cells business operations.Currently, the number of approved gene therapy is limited, however, a substantial number of products is anticipated to receive regulatory approvals in the forthcoming years. Growing R&D activities in gene therapy trials have resulted in an increase in market activities by the key stakeholders operating in the ATMP market. For instance, in April 2019, Catalent announced to acquire Paragon Bioservices to expand its business footprint in the gene therapy arena.

Regional Insights of Advanced Therapy Medicinal Products Market

The presence of a substantial number of approved ATMPs for use in U.S. has contributed to the large revenue share of this region. The recent approval of products like Kymriah, Yescarta, and Zolgensma has propelled the investment in the U.S. ATMP market. Furthermore, the U.S. FDA has announced that it has over 800 active Investigational New Drug applications on file by 2020 and the agency showed interest to receive more than 200 applications per year. In 2017, an estimated 391 gene therapy companies were operating in the U.S. market. In September 2019, around a hundred more companies including Big Pharma companies had entered the market. These factors are anticipated to accelerate the North America market at a lucrative CAGR in the forthcoming years.Europe is the second-largest pharmaceutical market globally, with Western Europe accounting for the large proportion of drug revenue. In the forthcoming years, cell therapy developers are anticipated to account for a major share of Europes drug revenues. In addition, the presence of a substantial number of academic institutes engaged in conducting early-stage cell therapy research is anticipated to boost the regional revenue growth. Furthermore, global companies are expanding their cell therapy manufacturing capabilities across Europe, thereby driving the regional market growth.

Market Share Insights of Advanced Therapy Medicinal Products Market

Currently, this market is a very active space. Recent approvals of ATMPs have prompted an unprecedented expansion in this area. Conventional drug makers are striving to gain a competitive advantage, considering ATMP as a lucrative source of revenue in the future healthcare systems. Companies are investing enormously in clinical trials of ATMP post the success of approved products. Some major players are Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd; and Organogenesis Inc.The companies are adopting various operating models to accelerate the product manufacturing process. While some companies undertake in-house production of therapies, a substantial number of players are preferring third-party service providers, including Contract Manufacturing Organizations (CMOs). The gene therapy contract development market space is driven by the surging demand that stems from the expansion of drug development pipeline and the rise in the number of start-ups that embrace human-testing but lack production capacities. On the other hand, several companies have marked their presence in the space by acquiring small and emerging CAR T-cell therapy developers.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Advanced Therapy Medicinal Products Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global advanced therapy medicinal products market report on the basis of therapy type and region:

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Cell Therapy

Stem Cell Therapy

Non-stem Cell Therapy

CAR-T Therapy

Gene Therapy

Tissue Engineered Product

Quick Read Table of Contents of this Report @ Advanced Therapy Medicinal Products Market Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026...

COVID-19 Impact On Global Adult Toys Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 – Cole of Duty

Posted on July 14, 2020 by Danzig

"Global Stem Cell Therapy Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Stem Cell Therapy market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Stem Cell Therapy Market. The report begins with the introduction on Stem Cell Therapy Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Stem Cell Therapy manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The Stem Cell Therapy production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Stem Cell Therapy Industry are:Osiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCRPharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Top Product Types Evaluated are:AutologousAllogeneic

Top Applications studied are:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

To derive the vital Stem Cell Therapy Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Stem Cell Therapy Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Stem Cell Therapy Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Stem Cell Therapy Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Stem Cell Therapy Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Stem Cell Therapy Market. North America is expected to reach a higher market share followed by the European region. Demand for Stem Cell Therapy products and its relevant applications across different market segments is growing rapidly.

Stem Cell Therapy Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Stem Cell Therapy Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Stem Cell Therapy industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Stem Cell Therapy Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

See the original post:

COVID-19 Impact On Global Adult Toys Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 - Cole of Duty

Cell Freezing Media for Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up…

Posted on July 14, 2020 by Danzig

New Jersey, United States,- Latest update on Cell Freezing Media for Cell Therapy Market Analysis report published with extensive market research, Cell Freezing Media for Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Cell Freezing Media for Cell Therapy industry. With the classified Cell Freezing Media for Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Cell Freezing Media for Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Cell Freezing Media for Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Cell Freezing Media for Cell Therapy Market growth opportunities in the industry.

Cell Freezing Media for Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Cell Freezing Media for Cell Therapy market size, volume and value, as well as price data.

Cell Freezing Media for Cell Therapy Market competition by top Manufacturers:

Cell Freezing Media for Cell Therapy Market Classification by Types:

Cell Freezing Media for Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Cell Freezing Media for Cell Therapy Market Report:

Cataloging the competitive terrain of the Cell Freezing Media for Cell Therapy market:

Unveiling the geographical penetration of the Cell Freezing Media for Cell Therapy market:

The report of the Cell Freezing Media for Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Cell Freezing Media for Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Cell Freezing Media for Cell Therapy Market report

About Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Follow this link:

Cell Freezing Media for Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up...

Select Page ::